fusafungin and Sinusitis

Topics: Acute Disease; Anti-Bacterial Agents; Child; Child, Preschool; Depsipeptides; Female; Fusarium; Humans; Male; Sinusitis

In a monocenter, placebo-controlled, double-blind, parallel-group study, 20 patients with acute symptoms of rhinosinusitis were treated with either fusafungine (CAS 1393-87-9, Locabiosol Dosier-Spray) (n = 10) or placebo nasal spray (n = 10). One patient from the placebo group was withdrawn from the study on the day of inclusion for noncompliance reasons. At the beginning of the 2-week treatment period, absence of an acute exacerbation of sinusitis with, e.g., opacity or fluid in any of the sinuses, was documented by computed tomography. Efficacy of treatment was assessed using objective measurements (e.g. sonography, rhinomanometry, acoustic rhinometry, and endoscopy) as well as scores recorded by the investigator on 6 consecutive visits before and after 1, 3, 7, 10, and 14 days of treatment, and by the patients on a diary card. Drug safety was evaluated on the basis of twice-daily assessment of general well-being and side effects. Statistical analysis of the data evidenced a positive effect of fusafungine as early as by the first 24 h of treatment (reduction of symptom score D0-->D1: p < 0.01), which was not seen in the placebo group (p = 0.2174). In the final assessment, both investigator and patients rated global efficacy better with fusafungine. In some instances, the intergroup difference achieved statistical significance (patient diaries, p = 0.0342). Side effects such as reactions at the application site mainly occurred in patients in the placebo group, who rated tolerability markedly worse than patients taking fusafungine (p = 0.0304; patient diaries, p = 0.0170).

Topics: Administration, Inhalation; Administration, Topical; Adult; Aerosols; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Depsipeptides; Double-Blind Method; Female; Fusarium; Humans; Male; Rhinitis; Rhinometry, Acoustic; Sinusitis; Ultrasonography

The aim of the study was to estimate by means of acoustic rhinometry (AR) the nasal blockade in 37 patients (5-73 years old, mean 32) with upper airways infections treated by fusafungine. The examinations were carried out on the first (D1) and seventh day (D7) of observation. Cross-sectional area (CA) mean values of 3 cm sector laid back to C notch of AR curves (CA-C3) were selected to the analysis.. The mean value of CA-C3: in all patients it was 2.61 cm2 on D1 and 2.8 cm2 on D7; in rhinitis and sinusitis patients--2.23 cm2, in others--3.16 cm2; without nasal discharge--3.48 cm2, in others (with severe or medium)--2.53 cm2 and 2.48 cm2 respectively. 29 patients had nasal blockade (78.4%) with mean CA-C3 = 2.34 cm2 (others--3.56, p < 0.05). During seven days the following enlargement of CA-C3 was reported: 14.9% in all patients (p < 0.01); in viral infections 24% (n = 14, p < 0.01), bacterial 14.3% (n = 11, NI); in nasal blockade patients--15.22%, others--13.55% (p < 0.01). Mean value of CA-C3 increased by 37.7% in patients who demonstrated, according to the physicians, "very good improvement", 5.7%--"good", 1.5%--"weak" (p < 0.05). There was also enlargement of nasal cavities in CA-C3 in non-sneezers (p < 0.05) and medium discharge symptom patients (p < 0.05). There was no statistical difference in clinical and acoustic rhinometry results between patients treated with fusafungine together with non-steroid anti-inflammatory drugs and patients treated with fusafungine.. AR is a good instrument to be used in the objective assessment of the nasal blockade changes in people with infection of the nasal mucosa and showed positive efficacy of fusafungine in the treatment of upper airway infection.

Topics: Acoustics; Adolescent; Adult; Aerosols; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Depsipeptides; Female; Fusarium; Humans; Male; Middle Aged; Nasal Obstruction; Paranasal Sinuses; Respiratory Tract Infections; Rhinitis; Sinusitis

An open, randomized, comparative trial of the drug bioparox was made in 50 patients. Nasal cavity function and its changes in response to bioparox administration were studied with the saccharin test and measurement of ciliary motor activity (CMA) using a special computer program. Significant suppression of the transport function and CMA in all the patients with catarrhal rhinosinusitis was observed. SMA on the inferior turbinated bone and septum was minimal, being low on the middle turbinated bone. After 7 days of bioparox administration mean value of CMA rose 2-fold. Thus, it is demonstrated that bioparox inhalations have no negative effect on nasal ciliated epithelium. On the contrary, it enhances its recovery.

Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Depsipeptides; Female; Fusarium; Humans; Male; Middle Aged; Nasal Mucosa; Rhinitis; Sinusitis

Topics: Acute Disease; Aerosols; Anti-Bacterial Agents; Depsipeptides; Fusarium; Humans; Immunoglobulin A; Sinusitis

Topics: Adolescent; Aerosols; Anti-Bacterial Agents; Child; Child, Preschool; Depsipeptides; Female; Fusarium; Humans; Male; Sinusitis

Topics: Adult; Aerosols; Anti-Bacterial Agents; Depsipeptides; Double-Blind Method; Endoscopy; Female; Fusarium; Humans; Male; Nasal Mucosa; Sinusitis